院外心脏骤停后轻度高碳酸血症与正常碳酸血症的比较
该研究将1700例院外心脏骤停后昏迷并收入ICU的成人随机分为24小时轻度高碳酸血症组(目标PaCO2 50–55 mm Hg)与正常碳酸血症组(目标PaCO2 35–45 mm Hg)。主要终点6个月良好神经功能结局(GOS-E评分≥5)在轻度高碳酸血症组为43.5%,正常碳酸血症组为44.6%(RR 0.98;95%CI 0.87–1.11;P=0.76)。6个月内死亡在两组分别为48.2%与45.9%(RR 1.05;95%CI 0.94–1.16)。不良事件发生率两组无显著差异。结论:目标轻度高碳酸血症未较正常碳酸血症带来更好的6个月神经功能结局。
要点
- 院外心脏骤停后昏迷成人,24小时目标PaCO2 50–55 mm Hg的轻度高碳酸血症未改善6个月良好神经功能结局(43.5% vs 44.6%;RR 0.98;95%CI 0.87–1.11;P=0.76)。
- 6个月内死亡在轻度高碳酸血症组为48.2%,正常碳酸血症组为45.9%(RR 1.05;95%CI 0.94–1.16)。
- 不良事件发生率两组无显著差异,原文未报告具体数值。
- 研究纳入17个国家63个ICU的1700例患者,轻度高碳酸血症组847例,正常碳酸血症组853例。
- 指南推荐院外心脏骤停后昏迷成人采用正常碳酸血症,本研究未显示轻度高碳酸血症更优。
适用人群与场景
- 院外心脏骤停后复苏成功并收入ICU的昏迷成人,骤停原因推测为心源性或未知。
诊断标准与关键阈值
- 良好神经功能结局定义为6个月时GOS-E评分5分(较低中度残疾)或更高(GOS-E范围1分[死亡]至8分,分数越高神经功能结局越好)。
处置流程与药物剂量
- 轻度高碳酸血症组:24小时内目标PaCO2 50–55 mm Hg。
- 正常碳酸血症组:24小时内目标PaCO2 35–45 mm Hg。
研究设计与关键结果
- 多中心随机对照试验,纳入17个国家63个ICU的1700例院外心脏骤停后昏迷成人,1:1随机分为24小时目标轻度高碳酸血症(PaCO2 50–55 mm Hg,847例)与目标正常碳酸血症(PaCO2 35–45 mm Hg,853例)。
- 主要终点6个月良好神经功能结局:轻度高碳酸血症组332/764例(43.5%),正常碳酸血症组350/784例(44.6%),RR 0.98(95%CI 0.87–1.11;P=0.76)。
- 次要终点6个月内死亡:轻度高碳酸血症组393/816例(48.2%),正常碳酸血症组382/832例(45.9%),RR 1.05(95%CI 0.94–1.16)。
- 不良事件发生率两组无显著差异。
证据类型、等级与局限
- 随机对照试验;原文未报告证据等级;局限:原文未报告局限性。
对床旁实践的改变
- 院外心脏骤停后昏迷成人采用目标PaCO2 35–45 mm Hg的正常碳酸血症策略,研究未显示目标轻度高碳酸血症(PaCO2 50–55 mm Hg)改善6个月神经功能结局。
- 作者结论:在院外心脏骤停后复苏的昏迷患者中,目标轻度高碳酸血症未较目标正常碳酸血症带来更好的6个月神经功能结局。
指南或共识出处
- TAME临床试验(ClinicalTrials.gov注册号NCT03114033),由澳大利亚国家健康与医学研究委员会等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Guidelines recommend normocapnia for adults with coma who are resuscitated after out-of-hospital cardiac arrest. However, mild hypercapnia increases cerebral blood flow and may improve neurologic outcomes.
METHODS: We randomly assigned adults with coma who had been resuscitated after out-of-hospital cardiac arrest of presumed cardiac or unknown cause and admitted to the intensive care unit (ICU) in a 1:1 ratio to either 24 hours of mild hypercapnia (target partial pressure of arterial carbon dioxide [Paco2], 50 to 55 mm Hg) or normocapnia (target Paco2, 35 to 45 mm Hg). The primary outcome was a favorable neurologic outcome, defined as a score of 5 (indicating lower moderate disability) or higher, as assessed with the use of the Glasgow Outcome Scale-Extended (range, 1 [death] to 8, with higher scores indicating better neurologic outcome) at 6 months. Secondary outcomes included death within 6 months.
RESULTS: A total of 1700 patients from 63 ICUs in 17 countries were recruited, with 847 patients assigned to targeted mild hypercapnia and 853 to targeted normocapnia. A favorable neurologic outcome at 6 months occurred in 332 of 764 patients (43.5%) in the mild hypercapnia group and in 350 of 784 (44.6%) in the normocapnia group (relative risk, 0.98; 95% confidence interval [CI], 0.87 to 1.11; P = 0.76). Death within 6 months after randomization occurred in 393 of 816 patients (48.2%) in the mild hypercapnia group and in 382 of 832 (45.9%) in the normocapnia group (relative risk, 1.05; 95% CI, 0.94 to 1.16). The incidence of adverse events did not differ significantly between groups.
CONCLUSIONS: In patients with coma who were resuscitated after out-of-hospital cardiac arrest, targeted mild hypercapnia did not lead to better neurologic outcomes at 6 months than targeted normocapnia. (Funded by the National Health and Medical Research Council of Australia and others; TAME ClinicalTrials.gov number, NCT03114033.).
参考来源
- Eastwood G, Nichol AD, Hodgson C, et al. Mild Hypercapnia or Normocapnia after Out-of-Hospital Cardiac Arrest. N Engl J Med. 2023. PMID: 37318140. doi:10.1056/NEJMoa2214552
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。